JPRN-UMIN000011682已完成2 期
Phase 2 study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) therapy for refractory/relapsed malignant lymphoma. - Phase 2 study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) therapy for refractory/relapsed malignant lymphoma.
TOHOKU HEMATOLOGY FORUM0 个研究点目标入组 30 人开始时间: 2013年9月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1 Neutrophils <1000/mm3 2 Platelet <75,000/mm3 3 Cre >1.5mg/dL 4 AST or ALT > 5xULN, T.Bil >2.0mg/dL 5 Angina pectoris, myocardial infarction, treatment required arrhythmia 6 Interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema 7 Patients with CNS invasion of lymphoma cells 8 Radiation therapy for thorax 9 Severe bacterial infection
研究者
相似试验
招募中
2 期
Phase II study of gemcitabine, carboplatin and dexamethasone with or without rituximab for patients with relapsed or refractory non-Hodgkin's lymphomarelapsed or refractory non-Hodgkin's lymphomaJPRN-UMIN000015998Gifu University Hospital20
进行中（未招募）
2 期
GHG-GCDrelapsed or refractory non-Hodgkin's lymphomaJPRN-jRCT1041230085Tsurumi Hisashi20
进行中（未招募）
不适用
A Phase II study of Gemcitabine and Bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma - GemBexEUCTR2006-000591-33-GBniversity College London84
进行中（未招募）
1 期
A study to elucidate the effect of gemcitabin and capcitabine in patients with colorectal cancer.Chemotherapy Refractory Metastatic Colorectal CancerMedDRA version: 14.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004182-33-DKVejle Hospital33
招募中
2 期
A Phase II study of Gemcitabine, Cisplatin and Bevacizumab for the patients with first recurrent and refractory ovarian clear cell carcinomaJPRN-UMIN000051087Kansai Clinical Oncology Group(KCOG)28